Terlizzi Kelly, Jaffe Ian S, Bisen Shivani S, Lonze Bonnie E, Orandi Babak J, Levan Macey L, Segev Dorry L, Massie Allan B
Department of Surgery, NYU Langone Health, New York, NY.
Department of Medicine, NYU Langone Health, New York, NY.
Transplantation. 2025 Jul 14. doi: 10.1097/TP.0000000000005467.
Transplant waitlist registrants in the United States may be delisted because of receipt of a transplant abroad. Although not universally unethical, "travel for transplantation" poses risks to posttransplant care. To better understand this phenomenon, this study identifies temporal trends, geographic patterns, and demographic factors associated with cross-border transplantation.
Using Scientific Registry of Transplant Recipients data, we identified 818 US waitlist candidates who were removed because of transplantation abroad between 2010 and 2023. We described recipient characteristics overall, by organ, and by top transplant destinations. We used a Cox regression framework to identify characteristics associated with waitlist removal due to transplantation abroad.
Transplants abroad averaged 58.4 per year. Incidence peaked at 80 transplants in 2017, with an upward trend after 2021. Kidney transplants made up 92.1% of cases. The most common destinations were the Philippines (19.8%), India (16.5%), Mexico (9.4%), China (8.4%), and Iran (4.4%). India and Mexico experienced the smallest drop-off during the height of the COVID-19 pandemic 2020-2021. Most recipients were US citizens (65.0%) or residents (23.5%). Female (adjusted hazard ratio [aHR], 0.520.610.71; P < 0.001) and Black candidates (aHR, 0.120.180.26; P < 0.001) were less likely to travel abroad compared with Asian candidates (aHR, 5.927.108.52; P < 0.001). Nonresidents (aHR, 6.708.6911.26; P < 0.001) and, among registrations in 2012 or later, nonresidents who traveled to the United States for transplantation (aHR, 27.2738.9155.50; P < 0.001) had a greater chance of undergoing transplantation abroad.
Understanding patterns of international travel for transplantation is key not only for preventing resource drains from destination countries but also for providing adequate posttransplant care for recipients.
在美国,移植等待名单上的登记者可能会因在国外接受移植而被除名。“出国移植”虽然并非普遍不道德,但会给移植后护理带来风险。为了更好地理解这一现象,本研究确定了与跨境移植相关的时间趋势、地理模式和人口统计学因素。
利用移植受者科学登记处的数据,我们确定了2010年至2023年间因在国外移植而被除名的818名美国等待名单候选人。我们描述了总体受者特征、按器官以及按主要移植目的地的特征。我们使用Cox回归框架来确定与因在国外移植而从等待名单上除名相关的特征。
每年平均有58.4例在国外进行移植。2017年移植例数达到峰值80例,2021年后呈上升趋势。肾移植占病例的92.1%。最常见的目的地是菲律宾(19.8%)、印度(16.5%)、墨西哥(9.4%)、中国(8.4%)和伊朗(4.4%)。在2020 - 2021年新冠疫情高峰期,印度和墨西哥的降幅最小。大多数受者是美国公民(65.0%)或居民(23.5%)。与亚洲候选人相比,女性(调整后风险比[aHR],0.52、0.61、0.71;P < 0.001)和黑人候选人(aHR,0.12、0.18、0.26;P < 0.001)出国移植的可能性较小。非居民(aHR,6.70、8.69、11.26;P < 0.001)以及在2012年或之后登记且前往美国进行移植的非居民(aHR,27.27、38.91、55.50;P < 0.001)在国外接受移植的机会更大。
了解出国移植的模式不仅对于防止目的地国家的资源流失至关重要,而且对于为受者提供充分的移植后护理也很关键。